Skip to content

Treatment of Screen-detected Celiac Disease

Treatment of Screen-detected Celiac Disease in Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01116505
Enrollment
40
Registered
2010-05-05
Start date
2008-08-31
Completion date
2012-08-31
Last updated
2012-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac Disease

Keywords

Celiac disease, Endomysial antibodies, Gluten-free diet, Screen-detected, Asymptomatic, Bone mineral density

Brief summary

The main purpose of this study is to evaluate the natural history of celiac disease in asymptomatic, screen-detected subjects having positive endomysial antibodies and the effects of an intervention with a gluten-free diet. The investigators hypothesize that these subjects may have decreased general health and benefit of the dietary treatment regardless of the small-bowel mucosal structure.

Detailed description

Asymptomatic, endomysial-antibody positive adults will be randomized to either continue with a normal, gluten-containing diet or start an intervention with a gluten-free diet irrespective of the small-bowel mucosal morphology. Several celiac-disease associated histological, serological and clinical markers will be evaluated both at baseline and after one year on trial.

Interventions

DIETARY_SUPPLEMENTGluten-free diet

gluten-containing cereals removed from diet

Sponsors

Tampere University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Positive endomysial antibodies * Adults

Exclusion criteria

* Previous celiac disease diagnosis * Significant clinical symptoms * Suspicion of any serious celiac disease-associated complication * Suspected or diagnosed severe illness other than celiac disease * Consuming oral corticosteroids or immune suppressants * Marked laboratory abnormalities

Design outcomes

Primary

MeasureTime frame
Small-bowel mucosal morphology and inflammationOne year

Secondary

MeasureTime frame
Tissue transglutaminase antibodiesone year
Antibodies to deamidated gliadinone year
Intestinal tissue transglutaminase-specific IgA depositsone year
Endomysial antibodiesone year
Body compositionone year
Health-related quality of lifeone year
Laboratory parametersone year
Bone mineral densityone year

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026